Builder Investment Group Inc. ADV Sells 335 Shares of Eli Lilly and Company (NYSE:LLY)

Builder Investment Group Inc. ADV lessened its position in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, Holdings Channel reports. The institutional investor owned 28,786 shares of the company’s stock after selling 335 shares during the quarter. Eli Lilly and Company comprises approximately 6.8% of Builder Investment Group Inc. ADV’s portfolio, making the stock its 2nd largest holding. Builder Investment Group Inc. ADV’s holdings in Eli Lilly and Company were worth $25,503,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. M&G Plc bought a new stake in shares of Eli Lilly and Company in the first quarter worth $8,896,000. Virtu Financial LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $2,138,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Mutual Advisors LLC increased its position in shares of Eli Lilly and Company by 404.8% in the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after acquiring an additional 50,197 shares during the last quarter. Finally, Private Advisor Group LLC increased its position in shares of Eli Lilly and Company by 0.6% in the first quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock valued at $59,345,000 after acquiring an additional 430 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Citigroup initiated coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,002.24.

Eli Lilly and Company Stock Down 1.3 %

NYSE LLY opened at $906.13 on Tuesday. The company has a market cap of $861.19 billion, a price-to-earnings ratio of 133.45, a PEG ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a 50 day moving average of $921.65 and a 200-day moving average of $859.57. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.